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DOI 10.1186/s12885-015-1029-zRESEARCH ARTICLE Open AccessNext generation sequencing of exceptional
responders with BRAF-mutant melanoma:
implications for sensitivity and resistance
Jennifer Wheler1*, Roman Yelensky2, Gerald Falchook1, Kevin B Kim3, Patrick Hwu3, Apostolia M Tsimberidou1,
Philip J Stephens2, David Hong1, Maureen T Cronin2 and Razelle Kurzrock4Abstract
Background: Patients with BRAF mutation-positive advanced melanoma respond well to matched therapy with
BRAF or MEK inhibitors, but often quickly develop resistance.
Methods: Tumor tissue from ten patients with advanced BRAF mutation-positive melanoma who achieved partial
response (PR) or complete response (CR) on BRAF and/or MEK inhibitors was analyzed using next generation
sequencing (NGS) assay. Genomic libraries were captured for 3230 exons in 182 cancer-related genes plus 37 introns
from 14 genes often rearranged in cancer and sequenced to average median depth of 734X with 99% of bases
covered >100X.
Results: Three of the ten patients (median number of prior therapies = 2) attained prolonged CR (duration = 23.6+
to 28.7+ months); seven patients achieved either a PR or a short-lived CR. One patient who achieved CR ongoing
at 28.7+ months and had tissue available close to the time of initiating BRAF inhibitor therapy had only a BRAF
mutation. Abnormalities in addition to BRAF mutation found in other patients included: mutations in NRAS, APC and
NF1; amplifications in BRAF, aurora kinase A, MYC, MITF and MET; deletions in CDKN2A/B and PAX5; and, alterations in
RB1 and ATM. Heterogeneity between patients and molecular evolution within patients was noted.
Conclusion: NGS identified potentially actionable DNA alterations that could account for resistance in patients with
BRAF mutation-positive advanced melanoma who achieved a PR or CR but whose tumors later progressed. A subset
of patients with advanced melanoma may harbor only a BRAF mutation and achieve a durable CR on BRAF pathway
inhibitors.
Keywords: BRAF mutation, Melanoma, Next generation sequencing, Resistance, Time to treatment failureBackground
Over 50% of melanomas are characterized by the pres-
ence of a BRAF mutation [1]. The most common BRAF
mutation (BRAF V600E) leads to constitutive activation
of the mitogen-activated protein kinase (MAPK) path-
way. Targeting BRAF with RAF-selective inhibitors has
demonstrated remarkable tumor shrinkage in those tu-
mors with BRAF mutations [2-4]. Despite these remarkable* Correspondence: jjwheler@mdanderson.org
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unless otherwise stated.results, response to BRAF inhibitors is transient for most
patients with advanced melanoma.
Previous pre-clinical studies have shown that retreat-
ment with a second BRAF inhibitor in cells that have
become resistant to another BRAF inhibitor is unlikely
to be an effective strategy [5]. Nor are secondary BRAF
mutations believed to play a large role after development
of resistance [6,7]. However, reactivation of MAPK path-
way through various mechanisms may be in part respon-
sible for the development of acquired resistance [6].
Combination strategies may help to overcome resistance.
For example, combining a BRAF inhibitor with agents
that target insulin-like growth factor 1 receptor (IGF1R),
downstream phosphatidylinositol 3-kinase (PI3K)/AKT. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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therapeutic effects [5,8]. Identification of molecular al-
terations in addition to BRAF may help explain why re-
sistance develops more quickly in some patients, and
suggest rationale strategies to overcome resistance.
In this pilot study, we investigated patients with ad-
vanced melanoma who were responders on clinical trials
using BRAF and/or MEK inhibitors.
Methods
Patients
Patients with BRAF-mutant, advanced melanoma who
experienced treatment failure with standard therapy, and
subsequent partial response (PR) or complete response
(CR) on BRAF, MEK, and BRAF/MEK combination tar-
geted trials, and who had tissue available for molecular
analysis were eligible. The study was carried out by col-
laboration between the Department of Investigational
Cancer Therapeutics (Phase I Clinical Trials Program) at
The University of Texas MD Anderson Cancer Center
(MD Anderson) and Foundation Medicine (Boston, MA).
The registration of patients in the database, pathology as-
sessment, and preliminary limited mutation analysis (see
below) were performed at MD Anderson. Subsequent
molecular evaluation with NGS was performed at Founda-
tion Medicine. The study was reviewed and approved
by the MD Anderson Institutional Review Board (IRB 5
IRB00006023) with a waiver of authorization to use and
disclose protected health information. All patients con-
sented for experimental therapeutic interventions ac-
cording to institutional guidelines, and all patients had
consented to anonymized assessments and analysis of
data and outcome of therapy.
Tissue samples and molecular analyses
Mutation analysis at MD Anderson: Archival formalin-
fixed, paraffin-embedded tissue blocks or material from
fine-needle aspiration biopsy obtained from diagnostic
and/or therapeutic procedures was used to test for BRAF
mutations. BRAF mutation testing was performed in the
CLIA–certified Molecular Diagnostic Laboratory within
the Division of Pathology and Laboratory Medicine at
MD Anderson. DNA was extracted from micro-dissected
paraffin-embedded tumor sections and analyzed using a
polymerase chain reaction (PCR)-based DNA sequencing
method for BRAF codons 595–600 mutations of exon
15 by pyrosequencing as previously described [9]. When-
ever possible, testing for other mutations such as Kirsten
rat sarcoma viral oncogene homolog (KRAS) and neuro-
blastoma rat sarcoma viral oncogene homolog (NRAS),
PIK3CA [10], and TP53 was performed. Phosphatase
and tensin homolog (PTEN) deletion was assessed
using immunohistochemistry and the DAKO antibody
(Carpinteria, Ca.) [11].NGS analysis at Foundation Medicine: Genomic librar-
ies were captured for 3230 exons in 182 cancer-related
genes plus 37 introns from 14 genes often rearranged in
cancer and sequenced to average median depth of 734X
with 99% of bases covered >100X [12] (Additional file 1).
The molecular alterations were reported as somatic alter-
ations of known significance and somatic alterations of
unclear significance based on the impact of these molecu-
lar alterations on tumorigenesis as stated in the scientific
literature.
Treatment and evaluation
Starting in July 2010, consecutive patients with melan-
oma and available tissue who achieved a PR or CR while
on a BRAF and/or MEK inhibitor were studied. Treat-
ment continued until disease progression or unacceptable
toxicity occurred.
Assessments were performed as specified in each pro-
tocol at the beginning of each new treatment cycle. Effi-
cacy was assessed using computed tomography and/or
positron emission tomography scan at baseline and then
every two cycles (eight weeks). All radiographs were read
in the Department of Radiology at MD Anderson. Re-
sponses were categorized per Response Evaluation Criteria
in Solid Tumors (RECIST) version 1.0 or 1.1 depending
on the study the patient was enrolled in (Additional file 2)
and were reported as best response [13,14].
Statistical analysis
This is a pilot study with descriptive analyses used to
summarize patient characteristics. Time to treatment
failure (TTF) was defined as the time interval from the
start of therapy to the first observation of disease pro-
gression per RECIST version 1.0 or 1.1 depending on the
study, or death, or removal from study for any reason.
Results
Patients
A total of ten patients with BRAF-mutant, advanced
melanoma who had achieved a PR or CR on a BRAF
and/or MEK targeted drug were analyzed for molecular
alterations. The median age was 52 years (range, 23 to
60 years) and all ten patients were Caucasian (100%).
These patients had received a median of two prior therap-
ies in the metastatic setting. Five patients had an Eastern
Cooperative Oncology Group (ECOG) performance status
[15] of 0 and five patients had an ECOG of 1. The patient
characteristics are summarized in Table 1.
Nine of ten patients with BRAF mutations were treated
with BRAF inhibitors, either as a single agent (7 patients)
or in combination with a MEK inhibitor (2 patients). The
remaining one patient was treated with a single-agent
MEK inhibitor. The clinical trials are summarized in
Additional file 2. Four of ten patients (40%) had a CR,
Table 1 Demographics and clinical characteristics of 10
patients with BRAF mutation- positive melanoma
Variable Group No. of
patients
%
(n = 10)
Age, years Median 52
Range 23-60
<50 5 50
≥50 5 50
Sex Men 7 70
Women 3 30
Race Caucasian 10 100
Number of prior
therapies
Median 2
Range 0-5
≤2 8 80
>2 2 20
Lactate dehydrogenasea ≤upper limit of normal 9 90
>upper limit of normal 1 10
TNM stage M1c No 6 60
Yes 4 40
ECOG PS 0 5 50
1 5 50
Therapy BRAF inhibitor alone 7 70
MEK inhibitor alone 1 10
BRAF/MEK inhibitor
combination
2 20
Treatment response Complete response 4 40
Partial response 6 60
aUpper limit of normal in our institution = 618 IU/L.
Abbreviations: ECOG Eastern Cooperative Oncology Group, PS Performance
Status, TNM tumor, node, metastasis.
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ger (TTF = 5.6, 23.6+, 27.4+, and 28.7+ months). Six
patients (60%) attained a PR (TTF = 3.0, 4.2, 5.7, 7.0,
7.9, and 11.2 months) (Figures 1 and 2).
Somatic genomic alterations
Eight of ten patients had results of NGS analysis per-
formed on tissues biopsied prior to treatment (range, 2
to 53 months) (Table 2). In two patients, NGS analyses
were done on tissues biopsied after treatment initiation;
in one case (case #4), the tissue for NGS analysis was
obtained six months after treatment initiation from a
continuously progressive lesion; in another case (case #5),
NGS analyses was performed on three different tissue
samples from progressive lesions (at 6, 9 and 26 months
after treatment initiation).
All patients harbored a BRAF V600E mutation. One
patient (case #2) had an additional BRAF T599S muta-
tion in exon 15. Seven of ten patients (70%) had somatic
alterations of known significance in addition to BRAFmutations (Table 2). In addition, seven out of ten pa-
tients (70%) had somatic alterations of unclear signifi-
cance (Additional file 3).
Molecular alterations in responding patients
Two of three patients (66%) with long term CR (28.7+
and 23.6+ months) (cases #1 and 3) had a BRAF muta-
tion as the only molecular alteration of known signifi-
cance and one of seven patients (14%) with transient
CR/PR had only a BRAF mutation (case #6). Alterations
of known significance found in other patients included
NRAS mutation (n = 2 patients), PTEN deletion (n = 1
patient), adenomatous polyposis coli (APC) mutation
(n = 1 patient), cyclin-dependent kinase inhibitor (CDKN)
2A or 2B deletion (n = 3 patients), PAX5 deletion (n = 1
patient), neurofibromin 1(NF1) mutation (n = 1 patient),
BRAF amplification (n = 2 patients), Aurora kinase A
amplification (n = 1), MET amplification (n = 1 patient),
microphthalmia-associated transcription factor (MITF)
amplification (n = 1 patient), and, v-myc avian myelocy-
tomatosis viral oncogene homolog (MYC) amplification
(n = 1 patient) (Table 2). New mutations within the BRAF
gene itself were not observed except in one case (case #2)
who attained a prolonged CR and had a T599S in addition
to a V600E mutation.
Responses in patients with simultaneous NRAS mutations
on treatment
NRAS mutations (Q61R and Q61K in codon 61) were de-
tected in two of ten patients (20%). One patient (case #4)
attained a PR (TTF = 11.2 months) and had an NRAS
mutation on NGS analysis from tissue taken from a
continuously progressing lesion 6 months after treatment
initiation; adequate tissue sample for testing before treat-
ment was not available. The other patient achieved a CR
(case #8; TTF = 5.6 months) and had an NRAS mutation
detected in a single PCR assay from a biopsy of the soli-
tary hepatic lesion that progressed after a brief period
of initial response (3.8 months after treatment initiation;
Figure 3), while the pre-treatment NGS analysis on this
patient failed to show an NRAS mutation (17 months be-
fore treatment).
Molecular evolution with progression
Several patients had more than one biopsy performed,
and molecular evolution was demonstrated in their results
of molecular analysis. One patient with a CR (case #8;
TTF = 5.6 months) had NGS analysis performed on a
pre-treatment biopsy (17 months before treatment) that
showed a BRAF and an NF1 mutation. Subsequently,
a second biopsy 3.8 months after treatment initiation
showed an NRAS mutation (Q61K) by single PCR-based
analysis (Table 2). One patient (case #5) had three dif-
ferent results on three different biopsy samples from
Figure 1 3-D waterfall plot. Best response by RECIST, of ten patients with BRAF-positive melanoma. Time to treatment failure in months is
represented by solid lines and the arrow indicates that the patient was still on study when the data was censored.
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initiation) by NGS analysis. The first, at 6 months after
treatment initiation, showed CDKN2A, CDKN2B and
PAX5 deletion (in addition to a BRAF mutation), while
the second at 9 months after treatment started, showed an
additional NF1 truncation. A third NGS analysis obtainedFigure 2 Time- to-treatment failure and additional molecular alteratio
that the patient was still on study when the data was censored. A compre
Additional file 3. Red text refers to alterations seen in post-treatment biops26 months after treatment initiation demonstrated only
alterations of unclear significance (Additional file 3). Of
interest, this patient was having a mixed response to
BRAF-targeted treatment at the time of the third biopsy.
That biopsy, which no longer showed the BRAF muta-
tion, was obtained from a tumor that was enlarging;ns in ten patients with BRAF-mutant melanoma. Arrow indicates
hensive list of alterations and their timing is found in Table 2 and
ies.
Table 2 NGS-based molecular alterations in BRAF-positive melanoma responders
Case
no.
BRAF
mutation
Type of targeted
drug
Treatment
start date
Best
response (%)
TTF
(months)a
Sampling date; time
from treatmentb
Molecular analysis by NGS
Mutations Amplifications/deletions Truncations
1 V600E BRAF inhibitor 9/17/2009 CR (−100) 28.7+ 5/1/2009; −4 months BRAF (V600E) None None
2 V600E BRAF inhibitor 10/7/2009 CR (−100) 27.4+ 1/22/2009; −9 months BRAF (V600E); BRAF (T599S) AURKA amplification; BRAF
amplification
None
T599S
3 V600E BRAF inhibitor 1/27/2010 CR (−100) 23.6+ 8/19/2005; −53 months Nonec None None
4 V600E BRAF +MEK inhibitor 11/11/2010 PR (−34) 11.2 5/17/2011; +6 months APC (R1171H); BRAF (V600E);
NRAS (Q61R)
PTEN deletion RB1 truncation
5 V600E BRAF inhibitor 6/17/2009 PR (−38) 7.9 12/2/2009; +6 months BRAF (V600E) CDKN2A deletion; CDKN2B deletion;
PAX5 deletion
None
3/23/2010; +9 months BRAF (V600E) CDKN2A deletion; CDKN2B deletion;
PAX5 deletion
NF1 truncation
8/24/2011; +26 months None None None
6 V600E MEK inhibitor 4/1/2010 PR (−53) 7.0 9/17/2007; −31 months BRAF (V600E) None None
7 V600E BRAF inhibitor 1/12/2010 PR (−48) 5.7 11/5/2009; −2 months BRAF (V600E) MITF amplification None
8 V600E BRAF +MEK inhibitor 9/3/2010 CR (−100) 5.6 4/7/2009; −17 months BRAF (V600E); NF1 (R 440*)d None None
9 V600E BRAF inhibitor 1/27/2010 PR (−75) 4.2 11/11/2009; −2 months BRAF (V600E) BRAF amplification; MET amplification;
CDKN2A deletion; CDKN2B deletion
ATM truncation
10 V600E BRAF inhibitor 4/15/2010 PR (−54) 3.0 12/11/2009; −4 months BRAF (V600E) MYC amplification; CDKN2A deletion None
a ‘+’ = continuing on the study when data was censored.
b ‘ + ’ = number of months biopsy was taken after treatment; '-' = number of months biopsy preceded treatment.
c = tissue sample obtained on 10/29/2008 was BRAF mutation-positive (V600E) by single PCR assay (case #3).
d = tissue sample obtained from a progressive hepatic lesion on 12/27/2010 had an NRAS mutation (Q61K) in codon 61 by single PCR assay (case #8).
Abbreviations: CR Complete response, NGS Next generation sequencing, PR Partial response, TTF Time to treatment failure.
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Figure 3 Computed tomography scans. A) at baseline, B) 2 months, and, C) 3.8 months after treatment initiation with a combination of a
MEK and BRAF inhibitor, of a patient (case #8) with short-lived CR (TTF = 5.6 months), who demonstrated an NRAS mutation in a biopsy obtained
3.8 months after treatment initiation. At 2 months, the liver lesion has regressed; at 3.8 months it recurred.
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regressing on BRAF-targeted therapy.
Timing of molecular analysis
One patient with an ongoing CR of 23.6+ months dur-
ation (case #3) had NGS analysis performed on a biopsy
obtained 53 months prior to treatment; no alterations of
known significance were demonstrated. A second biopsy
performed 15 months prior to treatment showed a V600E
BRAF mutation in a single PCR-based assay. This patient
illustrates a phenomenon of interest, i.e., patients with-
out BRAF mutations can acquire the mutation with
progression, and they can be sensitive to cognate tar-
geted inhibitors.
Another patient (case #6) with a biopsy 31 months
prior to treatment had only a BRAF mutation among the
alterations of known significance. This patient achieved
a PR lasting 7.0 months. All other patients with biopsies
performed 2 to 17 months prior to treatment had add-
itional alterations of known significance, except for one
individual (case #1) who had only a BRAF mutation and
achieved a CR that is ongoing at 28.7+ months.
Discussion
In order to better understand response and resistance,
we analyzed patients with BRAF -mutant, advanced mel-
anoma who achieved a PR or CR on a BRAF and/or
MEK targeted agent. Previous reports [16] provide proof
of principal for this next generation sequencing (NGS)
platform. NGS identified a broad range of molecular al-
terations (Table 2; Additional file 3).
Most patients (n = 7) had multiple additional alter-
ations of known oncogenic significance (Table 2). Path-
ways commonly affected, either directly or indirectly,
included the PI3K/AKT/mammalian target of rapamycin
(mTOR) axis (via PTEN alterations), the MAPK pathway
(via NRAS mutations or NF1 alterations), as well as tu-
mor suppressor signals (via CDKN2A or CDKN2B dele-
tion or RB1 truncation). Other abnormalities included
deletion in PAX5 (a paired box transcription factor), andamplifications in MET, BRAF and aurora kinase A. The
adenomatous polyposis coli (APC) gene responsible for
familial adenomatous polyposis, was mutated in one
patient; this gene, when aberrant, activates the Wnt sig-
naling pathway and induces chromosomal instability
[17,18]. Loss of its function also triggers the adenoma-
carcinoma transition in colorectal cancer [19]. Additional
mutations within the BRAF gene itself were not observed
except for patient #2 who attained a prolonged CR and
had a T599S in addition to a V600E mutation. BRAF amp-
lification was seen in two patients.
These additional molecular abnormalities were at times
evident long before treatment including, in one case,
17 months prior to starting targeted therapy (case #8).
Only three patients (cases #1, 3 and 6) had no additional
alterations of known significance as discerned by NGS,
and two of these individuals achieved a prolonged CR
with response ongoing 23.6+ months (case #3) and
28.7+ months (case #1), respectively, after starting treat-
ment with a BRAF inhibitor. The third patient (case #6)
achieved a transient PR (TTF = 7 months). In case #1,
the tissue sample was obtained only 4 months prior to
treatment. However, in cases 3 and 6, the tissue samples
were acquired 53 and 31 months, respectively, prior to
treatment; it is therefore unclear whether or not other
biologically-significant alterations might have emerged
closer to the time of treatment. One additional patient
with a prolonged CR (TTF = 27.4+ months; case #2) dem-
onstrated BRAF and aurora kinase A amplification in
addition to a BRAF mutation in a tissue sample obtained
9 months before treatment.
Several observations herein warrant further exploration.
First, it is conceivable that NGS analysis may reveal a sub-
set of advanced disease that can achieve prolonged CR on
a BRAF inhibitor alone. It is plausible that these patients
are the ones that have only a BRAF alteration, or only
alterations that influence a redundant signal. For most
patients with melanoma, the emergence of resistance is
expected. It is somewhat surprising that certain individ-
uals can achieve a CR while harboring numerous potential
Wheler et al. BMC Cancer  (2015) 15:61 Page 7 of 9driving alterations. For instance, the patient with a CR of
27.4+ months (case #2) had an NGS profile demonstrating
several possible driver alterations (BRAF and aurora
kinase A amplification) in addition to a BRAF mutation.
Amplifications in these genes are known to confer re-
sistance to treatment with BRAF inhibitors, though it
has been suggested that the resistance driven by BRAF
amplification can be overcome by higher doses of a
BRAF inhibitor [20] or by combining MEK and BRAF
inhibition [21]. The concept of oncogenic addiction
may explain response in such individuals [22].
NGS analysis may also provide information that can
be exploited to devise optimal combinations of targeted
agents for patients at the time of their initial therapy or
when resistance emerges. One patient who achieved a
CR, albeit of short duration (TTF = 5.6 months; case #8),
may have done so because he was treated with a com-
bination of a MEK and BRAF inhibitor. NGS revealed a
mutation in NF1 in addition to a V600E BRAF mutation.
NF1 is an upstream suppressor that can modulate MEK
signaling [23]. Such alterations confirm the need for
strategies that incorporate combinations including BRAF
and MEK inhibitors. In this patient, an NRAS mutation
(Q61K) emerged 3.8 months after treatment initiation,
which was demonstrated by a single PCR assay of the
tissue sampled from the solitary liver lesion that pro-
gressed after treatment. This might have accounted for
the patient’s relapse. The second patient (case #4) treated
with a MEK and BRAF inhibitor combination demon-
strated remarkable response (−34%; PR); a cystic lesion in
the chest wall eventually showed progression. Fine needle
aspiration cytology of the lesion revealed a Q61R mutation
in the NRAS gene and other molecular aberrations in
addition to the BRAF mutation.
Altogether two patients developed NRAS mutations
after treatment (Figure 2) (cases #4 and #8). The emer-
gence of an NRAS mutation is known to confer resist-
ance to BRAF inhibitors [7], and may therefore explain
the failure to achieve a durable response in these patients
(n = 1 with PR and n =1 with transient CR) [24,25]. The
presence of an NRAS mutation in addition to a BRAF mu-
tation in patients treated with BRAF inhibitors may reacti-
vate the MAP kinase (MAPK) pathway through CRAF [7].
Although MEK inhibitors might seem a rational choice
for patients bearing NRAS alterations as anti-tumor ac-
tivity has been reported in NRAS-mutant cutaneous me-
lanoma patients on MEK 162 [26], experience suggests
limited efficacy in such patients with other MEK inhibitors
[27]. It is unclear whether this is due to the fact that
NRAS signaling is incompletely extinguished by MEK in-
hibitors or if these tumors bear additional alterations that
confer resistance.
One patient had a PTEN deletion (case #4). Alterations
in the PI3K/AKT/mTOR pathway have been shown tobe operative in multiple tumors including melanoma [28].
For instance, PTEN loss is found in 30-50% of melanomas
[29], PIK3CA mutation in 3% [30], and changes in AKT
expression in some melanomas [31]. These are actionable
alterations in that multiple PIK3CA, AKT and mTOR in-
hibitors are in clinical trials or are already approved.
Recently, molecular evolution with progression and to
some degree heterogeneity between tumors in individual
patients has been described [32]. For instance, Wilmott
and colleagues [33] reported different subclones in tumor
tissue from a single metastatic site in a BRAF-mutant
melanoma patient, following progression of disease
after seven months of treatment with the BRAF inhibitor
vemurafenib; one clone had an additional NRAS mutation.
Our data supports such heterogeneity and demonstrates
the role that advanced molecular technology may play in
understanding and addressing mixed responses. For in-
stance, a patient (case #5) with a PR for 7.9 months had
three different biopsies from progressive lesions per-
formed at 6, 9 and 26 months after treatment initiation.
Each of these biopsies was analyzed using NGS and
each demonstrated different results. The first two ana-
lyses, at 6 and 9 months, showed CDKN2A, CDKN2B
and PAX5 deletions, but the sample obtained 9 month
after treatment initiation also showed an NF1 truncation,
probably indicating accumulation of additional changes
with disease progression. The results from a sample ob-
tained 26 months after treatment initiation, however,
showed no BRAF mutation, or other molecular alterations
of known significance. Of interest, the latter biopsy was
taken from a tumor that was increasing in size on a BRAF
inhibitor, while the other tumors had regressed.
There were several important limitations of this study.
First, it is a retrospective study and as such tissue sam-
ples were not collected at a uniform time. Second the
small number of patients in this pilot study precludes
statistical assessments. Third, we focused on responders.
Data on non-responders may be equally informative in
identifying the mechanisms that confer resistance.
This study demonstrates multiple additional molecular
alterations amongst BRAF mutation-positive patients with
advanced melanoma who achieved a CR or PR on BRAF
targeted agents. These alterations may be responsible for
the development of resistance to treatment with BRAF
and/or MEK inhibitors. We did not observe frequent new
mutations in the BRAF gene itself correlating with resist-
ance, consistent with the reported stability of the BRAF
mutation in melanoma [34]; unlike the situation with
other kinases such as BCR-ABL or epidermal growth fac-
tor receptor (EGFR), where resistance is often mediated
by acquisition of additional mutations within the same
gene. Given that some BRAF-mutant melanoma patients
fail to respond to BRAF inhibitors, and that the majority
of patients who do respond to BRAF/MEK inhibitors
Wheler et al. BMC Cancer  (2015) 15:61 Page 8 of 9eventually develop resistance, there is an urgent need to
identify possible combination treatments that may be ef-
fective. Of interest, some patients with advanced mela-
noma can achieve prolonged CR, and our investigation
suggests that some of these individuals may harbor only a
BRAFmutation despite the advanced state of their disease.
Further, patients can achieve CR while still harboring
aberrations other than those targeted by the agent given.
(In our study, 2 of the 4 patients who achieved CRs har-
bored additional aberrations: aurora kinase and BRAF
amplification in one patient, and an NF1 and NRAS muta-
tion in one patient). Therefore tumor complexity does not
preclude a complete response. Finally, while obtaining bi-
opsies close to the time of treatment may be ideal, our
study illustrates that data obtained from biopsies distant to
the time of treatment may still demonstrate aberrations
that could be responsible for response and/or resistance. A
concern that has been raised is whether patients with mul-
tiple aberrations can respond to targeted treatment of one
of those aberrations, or whether such treatment is futile.
Conclusion
Our study demonstrates that most of our excellent re-
sponders had multiple aberrations. Having these aberra-
tions may (or may not) preclude “cure”, but they do not
preclude an excellent response. Our study suggests that
further investigation of NGS for identification of action-
able molecular alterations before treatment and at the
time of resistance is warranted.
Additional files
Additional file 1: 182 cancer-related genes and 37 introns of 14
genes involved in rearrangements sequenced by NGS.
Additional file 2: Clinical trials and response assessment of 10
patients with BRAF mutation- positive melanoma.
Additional file 3: Other NGS alterations of unclear significancea.
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